Elekta AB (GB:0O5H)
LSE:0O5H
0O5H Stock Chart & Stats
kr56.70
-kr1.00(-1.60%)
At close: 4:00 PM EST
kr56.70
-kr1.00(-1.60%)
Day’s Range― - ―
52-Week Rangekr42.20 - kr66.60
Previous CloseN/A
Volume130.28K
Average Volume (3M)955.69K
Market Cap
kr20.98B
Enterprise Valuekr24.90B
Total Cash (Recent Filing)kr2.54B
Total Debt (Recent Filing)kr7.28B
Price to Earnings (P/E)546.4
Beta1.31
Next Earnings
Jun 03, 2026EPS Estimate
1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.88
Shares Outstanding368,587,650
10 Day Avg. Volume658,271
30 Day Avg. Volume955,692
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)2.13
Price to Sales (P/S)1.04
P/FCF Ratio17.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr52.50Price Target Upside-7.41% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)3.29
Revenue Forecast (FY)kr16.92B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationElekta’s reported ~SEK 2.0B of TTM free cash flow is a durable strength: it funds R&D, service investments, and working capital without relying solely on accounting profits. Strong cash conversion cushions the business through cycle variability and supports strategic reinvestment or debt reduction over months.
Recurring Installed-base RevenueThe company’s business model includes hardware sales plus high-margin, recurring streams—service contracts, software subscriptions, upgrades and spare parts—anchored to an installed base. These predictable annuity-like revenues support margin resilience and cash visibility over multi-year hospital procurement cycles.
Consistent Gross MarginsA roughly 38% gross margin indicates the core treatment systems and software generate meaningful unit-level profitability. Even with compressed net results, steady gross margins reflect product and pricing strength that can sustain contribution margins as the company adjusts operating costs or shifts mix toward higher-margin services.
Bears Say
Earnings Deterioration To Net LossThe transition from prior profitability to a TTM net loss signals structural pressure on bottom-line performance. Persistent losses can erode reserves, limit discretionary spending on product development and field support, and raise the bar for restoring ROE and operational momentum over the coming quarters.
Rising Leverage And Weaker EquityHigher debt-to-equity (~1.0) reduces balance-sheet flexibility, increasing interest and refinancing risk if cash flow weakens. Reduced equity cushions make the company more sensitive to cyclical downturns and limit capacity for bolt-on M&A or large capital investments without worsening leverage metrics.
Revenue And EPS WeaknessDeclining revenue and a >100% EPS contraction reflect demand or execution issues that are not transitory. Sustained top-line weakness undermines operating leverage, pressures margins and FCF durability, and could signal lost share or delayed hospital capital spending that would take multiple quarters to recover.
Elekta AB News
0O5H FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest share price was kr42.20 and its highest was kr66.60 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is kr20.98B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Jun 03, 2026 which is in 55 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Mar 05, 2026. The company reported kr0.88 earnings per share for the quarter, beating the consensus estimate of kr0.489 by kr0.391.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB does not currently pay dividends.
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate is 1.46.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of kr0.88 in its last earnings report, beating expectations of kr0.489. Following the earnings report the stock price went up 3.729%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in GB:0O5H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
0O5H Stock 12 Month Forecast
Average Price Target
kr52.50
▼(-7.41% Downside)
Technical Analysis
Vitrolife AB
―
Camurus AB
―
RaySearch Laboratories AB
―
C-Rad AB Class B
―
MedCap AB
―
Options Prices
Currently, No data available
---